1. Home
  2. EHI vs ACHV Comparison

EHI vs ACHV Comparison

Compare EHI & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Global High Income Fund Inc

EHI

Western Asset Global High Income Fund Inc

HOLD

Current Price

$5.99

Market Cap

183.6M

Sector

Finance

ML Signal

HOLD

Logo Achieve Life Sciences Inc.

ACHV

Achieve Life Sciences Inc.

HOLD

Current Price

$4.56

Market Cap

172.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EHI
ACHV
Founded
N/A
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
183.6M
172.0M
IPO Year
2003
2018

Fundamental Metrics

Financial Performance
Metric
EHI
ACHV
Price
$5.99
$4.56
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$14.67
AVG Volume (30 Days)
81.4K
1.2M
Earning Date
01-01-0001
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.80
$2.00
52 Week High
$6.70
$6.15

Technical Indicators

Market Signals
Indicator
EHI
ACHV
Relative Strength Index (RSI) 38.49 47.91
Support Level $5.80 $4.04
Resistance Level $6.46 $4.98
Average True Range (ATR) 0.08 0.41
MACD -0.01 -0.08
Stochastic Oscillator 22.22 17.95

Price Performance

Historical Comparison
EHI
ACHV

About EHI Western Asset Global High Income Fund Inc

Western Asset Global High Inc Fd Inc is a non-diversified, closed-end management investment company. Its investment objective is high current income and total return by investing in a world-wide portfolio of securities. The fund invests in various sectors such as Consumer Discretionary, Financials, Energy, Communication energy, Industrials, materials, and others.

About ACHV Achieve Life Sciences Inc.

Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.

Share on Social Networks: